Equity Overview
Price & Market Data
Price: $0.83
Daily Change: $0.00 / 0.00%
Daily Range: $0.69 - $1.03
Market Cap: $27,719,184
Daily Volume: 99,044
Performance Metrics
1 Week: 7.79%
1 Month: -6.64%
3 Months: 7.93%
6 Months: -33.06%
1 Year: -9.65%
YTD: 7.93%
Company Details
Employees: 15
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Israel
Details
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. The company was incorporated in 2017 and is headquartered in Herzliya, Israel.